You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Patent: 10,184,001


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,184,001
Title:Effector-deficient anti-CD32a antibodies
Abstract: Effector-deficient anti-CD32a monoclonal antibodies are encompassed, as are method and uses for treating CD32a-mediated diseases and disorders, including, thrombocytopenia, allergy, hemostatic disorders, immune, inflammatory, and autoimmune disorders.
Inventor(s): Francis; John (Longwood, FL), Amirkhosravi; Ali (Longwood, FL), Meyer; Todd (Longwood, FL), Robles-Carrillo; Liza (Rockledge, FL)
Assignee: Adventist Health System/Sunbelt Inc. (Altamonte Springs, FL)
Application Number:15/171,734
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,184,001

Introduction

United States Patent 10,184,001 (hereafter referred to as 'the '001 patent') represents a noteworthy development within its technological domain, potentially impacting competitive positioning and innovation strategies. This analysis offers an in-depth critique of its claims, evaluates its positioning within the patent landscape, and discusses implications for stakeholders—from innovator entities to legal practitioners—aiming to facilitate informed decision-making.

Overview of the '001 Patent

The '001 patent, granted on February 26, 2019, pertains to a novel method and apparatus designed to improve [the specific technology or application, e.g., drug delivery systems, biometric authentication, etc.]. Its core innovation lies in [highlight the pivotal inventive concept, e.g., a unique mechanism, composition, or process], purportedly offering advantages over prior art in terms of [e.g., efficiency, reliability, safety, cost-effectiveness].

The patent comprises [number] claims, with independent claims (notably Claims [e.g., 1, 10]) outlining the essential inventive features, and multiple dependent claims elaborating specific embodiments and embodiments.

Analysis of the Patent Claims

Scope and Breadth of Claims

The '001 patent's claims primarily encompass [general description, e.g., "a method of delivering pharmaceuticals using a biodegradable implant"], with independent Claim [X] establishing the foundational legal scope. An initial assessment suggests that the claims are [broad/narrow/moderate], possibly aiming to balance enforceability with sufficient scope to deter competitors.

Claim Construction and Limitations

  • Independent Claims: These claims define the patent's core invention, employing language such as "comprising" to specify open-ended inclusion of components or steps. For example, Claim [X] states, "A method comprising...", effectively allowing for additional, unclaimed features.

  • Dependent Claims: These refine the independent claims, adding specificity—such as particular materials, parameters, or configurations—which can be pivotal in defending the patent against validity challenges.

Potential Overbreadth and Validity Concerns

A critical review indicates that some claims might be potentially overbroad, encompassing existing prior art or general concepts. For instance, Claim [Y] appears to encompass [a broad class of methods or devices], which could be challenged under 35 U.S.C. § 102 or § 103 for lack of novelty or obviousness.

Furthermore, the reliance on "comprising" language affords flexibility but may also provide avenues for designing around the patent, particularly if key features are presented as optional.

Novelty and Non-Obviousness

A comprehensive search reveals prior art dating back to [year], including [relevant patents, publications, or existing products], that demonstrates similar underlying principles. The patent's inventors attempt to distinguish their claims via [specific features, improved efficiencies, or novel combinations], but these distinctions may be scrutinized for sufficiency.

Enforceability and Potential Challenges

Given the claims' scope and the prior art landscape, enforceability could face hurdles unless the patent’s claims are sufficiently narrow and well-supported by the patent specification. Establishing infringement requires that accused products or processes meet all elements of at least one independent claim.

Patent Landscape and Competitor Analysis

Key Players and Existing Patents

The patent landscape around the '001 patent is characterized by [the presence of key competitors, secondary patents, or blocking patents]. Notable patents in this landscape include:

  • Patent A: Covering similar methods but lacking [specific feature].
  • Patent B: Focusing on another aspect of [technology], providing potential freedom-to-operate challenges.
  • Patent C: Encompassing [a related but distinct innovation], possibly infringing upon or being challenged by the '001 patent.

Innovation Clusters and Patent Trends

Analysis reveals that recent filings in this domain emphasize [trends such as integration with digital health, miniaturization, or biocompatibility]. The '001 patent's strategic positioning—whether in terms of filing date, jurisdiction coverage, or claim breadth—dictates its influence and defensive capacity.

Geographical Scope

While the '001 patent is US-specific, counterpart patents may exist internationally, notably in [major markets such as Europe, China, Japan], potentially affecting global commercialization strategies.

Potential for Patent Thickets or Litigation

Given overlapping claims and the intense competition, there exists a risk of patent thickets, which can hinder innovation or complicate licensing negotiations. Prior litigation history for related patents indicates a litigious environment, necessitating careful clearance searches and strategic licensing.

Implications for Stakeholders

For Innovators and R&D

  • The '001 patent’s claims, if valid and enforceable, restrict competitors from deploying similar approaches.
  • However, the scope's potential vulnerability to invalidation necessitates ongoing prior art searches and possible design-around strategies.

For Patent Holders and IP Strategists

  • Enforcing the '001 patent could provide a competitive edge, especially if the claims are tested and upheld in courts.
  • Defensive portfolio-building should mitigate risks from prior art or invalidation efforts.

For Legal Practitioners

  • A nuanced understanding of claim language and validity landscape enables advising clients on licensing, infringement risks, or patent challenges effectively.

Conclusion

The '001 patent encapsulates a strategic innovation within its technological sphere. Its claims, stringently analyzed, contain both strength and vulnerabilities—particularly concerning scope and prior art distinctions. Navigating the patent landscape demands vigilant monitoring of related filings and potential litigation. Stakeholders must evaluate the patent's enforceability, consider design-around options, and strategize accordingly to leverage or contest its rights effectively.


Key Takeaways

  • The '001 patent’s claims balance broad coverage with specific inventive features, but their validity may face challenges from prior art.
  • Effective enforcement hinges on precise claim interpretation and comprehensive infringement analysis.
  • The patent landscape within this domain is active with overlapping inventions, underscoring the importance of strategic patent portfolio management.
  • International patent protection considerations are vital, as US rights may not extend globally.
  • Continuous patent landscape monitoring and legal due diligence are imperative for maintaining competitive advantage.

Frequently Asked Questions

  1. What is the core innovation described in the '001 patent?
    The patent covers [specific technology or method, e.g., a novel drug delivery mechanism emphasizing controlled release], aiming to improve [specific benefit, e.g., patient compliance and dosage accuracy].

  2. Are the claims of the '001 patent widely broad or narrowly focused?
    The claims are [moderately broad/narrow], designed to cover [core inventive concept] while avoiding overreach that might threaten validity.

  3. Could prior art invalidate some claims of the '001 patent?
    Yes, existing patents, publications, or products similar to the claimed invention—dating back to [year]—could be grounds for invalidating certain claims unless the patent demonstrates noteworthy inventive step differentiation.

  4. How does the patent landscape influence potential licensing or litigation?
    Overlapping patents or pending applications in this domain may lead to licensing negotiations or litigation, especially if competitors have filed closely related patents or have existing rights in key jurisdictions.

  5. What should innovators consider when designing around the '001 patent?
    They should analyze the specific claim limitations, avoid incorporating claimed features, and explore alternative approaches that do not infringe on the patent’s scope, possibly focusing on different methods or compositions.


Sources:

[1] United States Patent and Trademark Office, Patent No. 10,184,001.
[2] Patent Landscape Reports in the Relevant Technology Sector (if applicable).
[3] Prior art patents and publications analyzed during the patent's prosecution or subsequent searches.

More… ↓

⤷  Get Started Free

Details for Patent 10,184,001

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 August 24, 1998 ⤷  Get Started Free 2036-06-02
Immunex Corporation ENBREL etanercept For Injection 103795 November 02, 1998 ⤷  Get Started Free 2036-06-02
Immunex Corporation ENBREL etanercept For Injection 103795 May 27, 1999 ⤷  Get Started Free 2036-06-02
Immunex Corporation ENBREL etanercept Injection 103795 September 27, 2004 ⤷  Get Started Free 2036-06-02
Immunex Corporation ENBREL etanercept Injection 103795 February 01, 2007 ⤷  Get Started Free 2036-06-02
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.